Skip to main content

8 Result(s)

within Martin Czejka Remove this filter

and

  1. No Access

    Article

    Sex-Related Differences in Pharmacokinetics and Pharmacodynamics of Frequently Prescribed Drugs: A Review of the Literature

    While there is considerable evidence about sex-related differences between men and women in drug metabolism, efficacy and safety of frequently prescribed drugs such as analgesics, tranquillizers, statins and b...

    André Farkouh, Thomas Riedl, Roman Gottardi, Martin Czejka… in Advances in Therapy (2020)

  2. No Access

    Article

    Hepatic arterial infusion of irinotecan and EmboCept® S results in high tumor concentration of SN-38 in a rat model of colorectal liver metastases

    Intraarterial chemotherapy for colorectal liver metastases (CRLM) can be applied alone or together with embolization particles. It remains unclear whether different types of embolization particles lead to high...

    Anne Kauffels, Marie Kitzmüller, Andrea Gruber… in Clinical & Experimental Metastasis (2019)

  3. No Access

    Article

    Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial

    Background Purpose of this phase Ib trial was to establish the maximum tolerable dose (MTD) of capecitabine and to escalate the dosages of erlotinib and bevacizumab to determine the recommended phase II dose (RP2...

    Christian Dittrich, Robert Königsberg, Martina Mittlböck… in Investigational New Drugs (2019)

  4. Article

    Open Access

    Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model

    In this study, a therapeutic drug monitoring (TDM) of erlotinib in pancreatic cancer patients was performed over 50 weeks to reveal possible alterations in erlotinib plasma concentrations. Additionally, a phys...

    Andrea Gruber, Martin Czejka, Philipp Buchner… in Cancer Chemotherapy and Pharmacology (2018)

    Download PDF (873 KB) View Article

  5. No Access

    Chapter

    Pharmacokinetic Aspects of Regional Tumor Therapy

    The aim of a safe and efficient drug therapy is to direct the agent as near as possible to its target where it generates its maximum pharmacological effect while kee** side effects at a minimum.

    Martin Czejka, Marie Kathrin Kitzmüller in Locoregional Tumor Therapy (2018)

  6. No Access

    Chapter

    Pharmacokinetic Aspects of Regional Tumor Therapy

    The aim of a safe and efficient drug therapy is to direct the agent as near as possible to its target where it generates its maximum pharmacological effect while kee** side effects at a minimum.

    Martin Czejka, Katharina Schüller in Locoregional Tumor Therapy (2015)

  7. No Access

    Article

    Plasma disposition of capecitabine and its metabolites 5′DFCR and 5′DFUR in a standard and dose-intensified monotherapy regimen

    In view of a potential gain in anticancer activity in advanced colorectal cancer (ACRC), there has been considerable interest in using a higher than the approved standard dose of capecitabine (CCB) combined wi...

    Martin Czejka, J. Schueller, A. Farkouh… in Cancer Chemotherapy and Pharmacology (2011)

  8. No Access

    Article

    Pharmacokinetic interaction of 5-fluorouracil and interferon alpha-2b with or without folinic acid

    The purpose of this study was to evaluate a potential pharmacokinetic (PK) interaction between fluorouracil (5-FU) and the biomodulating agent interferon alpha (IFN-α) in patients with metastatic colorectal ca...

    Johannes Schüller, Martin Czejka in Medical Oncology (1995)